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A {#sec1}
=

Abdominal catastrophes

 in ICU, **1017--1044**. *See also specific types, e.g.,* Abdominal compartment syndrome

 treatment of, 1032--1037

 antimicrobial, 1032--1034

 surgical, 1034--1037

Abdominal compartment syndrome, 1018--1021

 background of, 1018

 clinical presentation of, 1019--1020

 diagnosis of, 1020--1021

 epidemiology of, 1018--1019

 surgical management of, 1035

Abdominal organ transplant recipients

 life-threatening infections in, 960

ACCB. *See Acinetobacter baumannii* (ACCB)

Acidosis

 severe malaria and

 management of, 876

*Acinetobacter baumannii* (ACCB)

 resistant

 management of, 912--913

Acute acalculous cholecystitis, 1029--1031

 background of, 1029--1030

 diagnosis of, 1030--1031

 epidemiology of, 1030

Acute intestinal ischemia, 1021--1024

 background of, 1021--1022

 clinical presentation of, 1023--1024

 diagnosis of, 1023--1024

 epidemiology of, 1022--1023

Acute respiratory distress syndrome (ARDS)

 influenza A 2009 H1N1 and

 management of, 1075--1077

Adenoviral infections, 1052--1059, 1077--1078

 AIDS and, 1056--1057

 clinical manifestations of, 1053--1055

 congenital immune deficiency and, 1056

 diagnosis of, 1057--1058

 epidemiology of, 1053

 management of, 1058--1059

 microbiology of, 1052--1053

 solid-organ transplantation and, 1055--1056

Adenovirus, 1077--1079

AIDS

 adenoviral infections related to, 1056--1057

Aminoglycoside(s)

 aerosolized

 for respiratory infections, 906--907

 in VRE management

 resistance to, 845

AmpC--producing Enterobacteriaceae

 management of, 910

Anemia

 severe malaria and

 management of, 876

Antimicrobial agents

 for abdominal catastrophes in ICU, 1032--1034

 empiric

 in severe malaria management, 874

 in infective endocarditis management, 928

 for MDR GNB infections, 900--903

 in NSTIs management, 800

 in severe *Clostridium difficile* infection management, 831--832

 in SSI management, 891--892

 in VRE management

 newer agents, 843--845

ARDS. *See* Acute respiratory distress syndrome (ARDS)

Artemisinin derivatives

 in severe malaria management, 869--872

Aspergillosis

 invasive pulmonary

 in COPD patients, 811

*Aspergillus* spp.

 transplant infections related to, 965--966

Avibactam

 for MDR GNB infections, 903

Aztreonam

 for MDR GNB infections, 902

B {#sec2}
=

β-lactam(s)

 for MDR GNB

 extended infusion of, 903, 906

 in VRE management

 resistance to, 845

Bacteremia

 VRE and, 842

Bacterial meningitis

 community-acquired

 in cirrhotic patients, 815--816

BAL30376

 for MDR GNB infections, 903

Bariatric surgery

 SSIs after, 892--893

BLI-489

 for MDR GNB infections, 903

Blood transfusion

 in severe malaria management, 876

Bloodstream infections (BSIs)

 catheter-related, 992

 in CKD patients, 813

 in HSCT recipients, 960

 infusate-related, 992

BSIs. *See* Bloodstream infections (BSIs)
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=

*Candida* sepsis

 control of, 856--857

 diagnosis of, 855--856

 risk factors for, 854--855

 significance to ICU physicians, **853--864**

 treatment of, 857--859

 drug-drug interactions in, 859--860

CAP. *See* Community-acquired pneumonia (CAP)

Carbapenem-resistant Enterobacteriaceae (CRE)

 management of, 910--912

Cardiothoracic transplant recipients

 life-threatening infections in, 959--960

Catheter(s)

 vascular

 septic risk specific to, 1001--1002

Catheter colonization

 catheter- and infusion-related sepsis due to, 991

Catheter infection, 991

Catheter-related bloodstream infections (CRBSIs), 992

 in CKD patients, 813

Catheter-related sepsis, **989--1015**

 BSIs and, 813, 992

 catheter material and, 1001

 causes of, 990--992

 epidemiology of, 990--992

 introduction, 989--990

 management of, 1002--1003

 prevention of, 1003--1004

 catheter-design improvements/antiseptic-antimicrobial bonding in, 1006--1007

 duration of intravascular catheterization in, 1007

 insertion site in, 1007

 integrative, multifactorial protocols in, 1007

 vascular catheter--related, 1001--1002

Central nervous system (CNS) infections, **975--987**

 causes of, 976--979

 diagnosis of, 983--984

 history of, 975--976

 late post-transplant, 962--963

 natural history of, 981--983

 nomenclature of, 975--976

 pathogenesis of, 976

 pathophysiology of, 976, 980--981

 treatment of, 984--985

Central venous catheter insertion sites, 1001

Cerebral malaria

 diagnosis of

 in endemic settings, 868--869

 management of, 875

Cholecystitis

 acute acalculous, 1029--1031. *See also* Acute acalculous cholecystitis

 surgical management of, 1035--1036

Chronic kidney disease (CKD)

 life-threatening infections in patients with, 812--814

 CAP, 813

 CRBSIs, 813

 epidemiology of, 812--813

 peritonitis, 813

 treatment of, 813--814

Chronic obstructive pulmonary disease (COPD)

 life-threatening infections in patients with, 810--812

 acute exacerbation of, 810

 CAP, 810--811

 epidemiology of, 810

 invasive pulmonary aspergillosis, 811

 treatment of, 811--812

Cirrhosis

 life-threatening infections in patients with, 814--817

 CAP, 815

 community-acquired bacterial meningitis, 815--816

 endotipsitis, 816

 epidemiology of, 814

 SBP, 815

 SSTIs, 815

 treatment of, 816--817

CKD. *See* Chronic kidney disease (CKD)

*Clostridium difficile* infection

 background of, 827--828

 in early posttransplant period, 959

 severe, **827--839,** 1027--1029

 background of, 1027--1028

 causes of, 1027--1028

 clinical manifestations of, 828--829

 diagnosis of, 829--830, 1028--1029

 epidemiology of, 828, 1028

 management of

 antimicrobial, 831--832

 general, 830--831

 supportive care in, 830--831

 surgical indications in, 832--833

 overview of, **827--839**

 prevention of, 834

 surgical management of, 1034--1035

CMV\. *See* Cytomegalovirus (CMV)

CNS infections. *See* Central nervous system (CNS) infections

Coagulase-negative staphylococci (CONS)

 infective endocarditis related to, 932

Colitis

 ischemic, 1024--1027. *See also* Ischemic colitis

Colon

 ischemia of, 1021--1032. *See also specific types, e.g.,* Ischemic colitis

Community-acquired bacterial meningitis

 in cirrhotic patients, 815--816

Community-acquired pneumonia (CAP)

 in cirrhotic patients, 815

 in COPD patients, 810--811

 life-threatening infections in patients with, 813

Congenital immune deficiency

 adenoviral infections related to, 1056

CONS. *See* Coagulase-negative staphylococci (CONS)

Contamination

 catheter- and infusion-related sepsis due to, 991

COPD. *See* Chronic obstructive pulmonary disease (COPD)

Coronavirus(es), 1078--1079

 human, 1046--1050. *See also* Human coronavirus infections

CRBSIs. *See* Catheter-related bloodstream infections (CRBSIs)

CRE. *See* Carbapenem-resistant Enterobacteriaceae (CRE)

Culture-negative endocarditis, 933

Cytomegalovirus (CMV)

 transplant infections related to, 963--964
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Daptomycin

 in VRE management, 843

 resistance to, 846

Diabetes mellitus

 life-threatening infections in patients with, 808--810

 epidemiology of, 808

 fungal infections, 809

 SSTIs, 809

 treatment of, 809--810

 UTIs, 808

Doripenem

 for MDR GNB infections, 901

Duodenal ulcer

 perforated, 1031--1032

 surgical management of, 1037

E {#sec5}
=

Ebstein-Barr virus (EBV)--associated PTLD

 transplant infections related to, 964--965

Echocardiography

 in infective endocarditis diagnosis and management, 926--928

 pitfalls of, 927--928

 transesophageal

 in infective endocarditis diagnosis and management, 926--927

 transthoracic

 in infective endocarditis diagnosis and management, 926--927

Endocarditis

 culture-negative, 933

 epidemiology of, 923--924

 incidence of, 923

 infective

 in ICU, **923--951**. *See also* Infective endocarditis

 prosthetic valve, 933--935. *See also* Prosthetic valve endocarditis (PVE)

 VRE and, 842

Endotipsitis

 in cirrhotic patients, 816

Enterobacteriaceae

 AmpC--producing

 management of, 910

 carbapenem-resistant

 management of, 910--912

 ESBL--producing

 management of, 907, 910

Enterococcus(i)

 infective endocarditis related to, 931

 vancomycin-resistant, **841--852**. *See also* Vancomycin-resistant enterococci (VRE)

Enterocolitis

 typhlitis/neutropenic

 in HSCT recipients, 961

Enterocolitis/colitis

 late post-transplant, 963

ESBL--producing Enterobacteriaceae. *See* Extended β-lactamase (ESBL)--producing Enterobacteriaceae

Exit-site infection, 991

Extended β-lactamase (ESBL)--producing Enterobacteriaceae

 management of, 907, 910

F {#sec6}
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Fluid management

 in severe malaria management, 873--874

Foreign body(ies)

 implanted

 SSIs related to, 892

Fosfomycin

 for MDR GNB infections, 901

Fungal infections

 in diabetic patients, 809

Fungus(i)

 PVE related to, 934

G {#sec7}
=

G-CSF. *See* Granulocyte colony-stimulating factor (G-CSF)

GNB. *See* Gram-negative bacilli (GNB)

Gram-negative bacilli (GNB)

 MDR

 infections caused by. *See* Gram-negative infections, MDR GNB

 management of

 antimicrobial, 900--903

 effectiveness of, 903, 908--909

 optimizing agents in, 903, 906--907

 PVE related to, 934

 resistant

 global surveillance data for, 898--899

 infections caused by. *See* Gram-negative infections, resistant

Gram-negative infections

 MDR GNB

 defined, 896--900

 diagnosis of, 896--900

 management of

 adjuvant therapy in, 914

 resistant, **895--921**

 background of, 895--896

 defined, 896--900

 diagnosis of, 896--900

 epidemiology of, 896

 management of, 900

 ACCB, 912--913

 AmpC--producing Enterobacteriaceae, 910

 CRE, 910--912

 effectiveness of, 903

 ESBL--producing Enterobacteriaceae, 907, 910

* Pseudomonas aeruginosa,* 913--914

* Stenotrophomonas maltophilia,* 914

Granulocyte colony-stimulating factor (G-CSF)

 in cirrhosis management, 817
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=

HACEK organisms

 infective endocarditis related to, 932

HACEK PVE, 934

Hand washing

 in catheter- and infusion-related sepsis prevention, 1004

Hantavirus pulmonary syndrome, 1059--1060

 clinical and pathologic features of, 1059--1060

 diagnosis of, 1060

 introduction, 1059

 prevention of, 1060

 treatment of, 1060

Heart failure (HF)

 life-threatening infections in patients with, 817--818

 epidemiology of, 817

 management of, 818

Hematopoietic stem cell transplant (HSCT) recipients

 life-threatening infections in, 960--961

HF. *See* Heart failure (HF)

hMPV. *See* Human metapneumovirus (hMPV)

HSCT recipients. *See* Hematopoietic stem cell transplant (HSCT) recipients

Human coronavirus infections, 1046--1050

 clinical manifestations of, 1047--1048

 course of, 1047--1048

 diagnosis of, 1048--1049

 epidemiology of, 1046--1047

 pathogenesis of, 1047

 transmission of, 1046--1047

 treatment of, 1049--1050

 virology of, 1046

Human metapneumovirus (hMPV), 1079--1080

Hydrocortisone therapy

 in cirrhosis management, 817

Hypotension

 severe malaria and

 management of, 874

I {#sec9}
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Immune deficiency

 congenital

 adenoviral infections related to, 1056

Immunocompromised patients

 medically

 life-threatening infections in, **807--826**. *See also specific infections and* Life-threatening infections, in medically immunocompromised patients

Implanted foreign body(ies)

 SSIs related to, 892

Infection(s). *See also specific types*

 bloodstream. *See* Bloodstream infections (BSIs)

 catheter, 991

* Clostridium difficile*

 severe, **827--839**

 CNS, **975--987**. *See also specific types and* Central nervous system (CNS) infections

 exit-site, 991

 gram-negative. *See* Gram-negative infections

 necrotizing soft tissue, **795--806**. *See also* Necrotizing soft tissue infections (NSTIs)

 surgical site, **887--894**. *See also* Surgical site infections (SSIs)

Infective endocarditis, **923--951**

 causes of, 924

 CONS and, 932

 diagnosis of

 echocardiography in, 926--928

 TTE in, 926--927

 enterococcal, 931

 epidemiology of, 923--924

 HACEK organisms and, 932

 in ICU, **923--951**

 described, 925

 management of, 928--929

 neurologic complications, 925--926

 severe sepsis or septic shock in patient with

 management of, 929

* Streptococcus gallolyticus* and, 930--931

 viridans streptococci and, 930--931

 incidence of, 923--924

 management of

 antimicrobial, 928

 echocardiography in, 926--928

 supportive care in, 928

 surgical, 935--942

 follow-up care, 942

 indications for, 935--937

 procedures, 941--942

 timing of, 937, 940--941

 MRSA and, 932

 natural valve, 929--930

 staphylococcal, 931

Influenza A 2009 H1N1, 1071--1077

 ARDS secondary to

 management of, 1075--1077

 clinical presentation of, 1073--1074

 described, 1071--1072

 diagnosis of, 1073--1074

 pathophysiology of, 1074--1075

 pulmonary pathology of, 1075

 respiratory failure related to

 epidemiology of, 1072--1073

 risk factors for, 1072--1073

Influenza virus

 described, 1070--1071

 endemic viral pneumonia related to, **1069--1086**. *See also* Viral pneumonia(s)

Infusion-related sepsis, **989--1015**

 BSIs and, 992

 diagnosis of, 994--996

 epidemiology of, 990--992

 management of, 1002--1003

 microorganisms associated with, 996--998

 pathogenesis of, 992--994

 prevention of, 1003--1004

 insertion site in, 1007

 integrative, multifactorial protocols in, 1007

 risk factors for, 998--1000

Infusion system protocols, 1006

Infusion therapy

 dedicated

 in catheter- and infusion-related sepsis prevention, 1004

Intensive care unit (ICU)

 infective endocarditis in, **923--951**. *See also* Infective endocarditis

 severe malaria in

 management of, **865--885**. *See also* Malaria, severe

Intensive care unit (ICU) physicians

* Candida* sepsis significance to, **853--864**

Intra-abdominal complications

 background of, 1017--1018

 in ICU, **1017--1044**. *See also specific types*

Intravascular catheter dressing protocol, 1005

Intravascular catheter insertion

 surgical aseptic technique for, 1005

Invasive pulmonary aspergillosis

 in COPD patients, 811

Ischemia(s)

 of small intestine and colon

 in ICU, 1021--1032. *See also specific types, e.g.,* Acute intestinal ischemia

Ischemic bowel disease

 surgical management of, 1036--1037

Ischemic colitis, 1024--1027

 background of, 1024--1025

 clinical presentation of, 1025--1027

 diagnosis of, 1025--1027

 epidemiology of, 1025

K {#sec10}
=

Kidney disease

 chronic

 life-threatening infections in patients with, 812--814. *See also* Chronic kidney disease (CKD)

L {#sec11}
=

Life-threatening infections

 in medically immunocompromised patients, **807--826**

 cirrhosis, 814--817

 CKD, 812--814

 COPD, 810--812

 diabetes mellitus, 808--810

 HF, 817--818

 introduction, 807--808

 pathogenesis of, 808

Linezolid

 in VRE management

 resistance to, 846

M {#sec12}
=

Malaria

 cerebral

 diagnosis of

 in endemic settings, 868--869

 management of, 875

 severe

 acidosis in

 management of, 876

 anemia in

 management of, 876

 background of, 865--866

 defined, 867

 diagnosis of, 867--869

 current innovations in, 869

 epidemiology of, 866--867

 hypotensive shock in

 management of, 874

 management of, 869--877

 adjunctive therapies in, 877--878

 artemisinin derivatives in, 869--872

 blood transfusion in, 876

 empiric antimicrobials in, 874

 fluids in, 873--874

 in ICU, **865--885**

 oral agents in, 872--873

 quinidine in, 872

 quinine in, 872

 supportive care in, 873--876

* Plasmodium* parasites and

 life cycle of, 866

 respiratory distress in

 management of, 875--876

 suspected

 initial management of, 869

 untreated

 fatal outcomes of, 877, 879

Medically immunocompromised patients

 life-threatening infections in, **807--826**. *See also specific infections and* Life-threatening infections, in medically immunocompromised patients

Meningitis

 bacterial

 community-acquired

 in cirrhotic patients, 815--816

 VRE and, 842

Methicillin-resistant *Staphylococcus aureus* (MRSA)

 infective endocarditis related to, 932

Minocycline

 for MDR GNB infections, 901--902

Mold(s)

 transplant infections related to, 966

MRSA. *See* Methicillin-resistant *Staphylococcus aureus* (MRSA)

Multidrug-resistant (MDR) gram-negative bacilli (GNB)

 resistant

 infections caused by. *See* Gram-negative infections, MDR GNB

N {#sec13}
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Natural valve infective endocarditis, 929--930

Necrotizing soft tissue infections (NSTIs), **795--806**

 background of, 795

 diagnosis of, 796--799

 clinical clues in, 797

 described, 796--797

 frozen section biopsy in, 799

 imaging studies in, 799

 laboratory findings in, 797--799

 operative exploration in confirmation of, 799

 epidemiology of, 796

 incidence of, 796

 management of

 antimicrobial, 800

 costs related to, 804

 outcomes of, 803

 rehabilitation in, 803

 supportive care in, 802--803

 surgery, 800--802

 mortality related to, 795--796

Neurologic complications

 infective endocarditis and, 925--926

NSTIs. *See* Necrotizing soft tissue infections (NSTIs)

O {#sec14}
=

Obese patients

 post-bariatric surgery

 SSIs in, 892--893

P {#sec15}
=

Perforated duodenal ulcer, 1031--1032

 surgical management of, 1037

Peritonitis

 in CKD patients, 813

 spontaneous bacterial

 in cirrhotic patients, 815

PJP/PCP. *See Pneumocystis jirovecci* pneumonia(PJP)/PCP

*Plasmodium* parasites

 life cycle of, 866

Plazomicin

 for MDR GNB infections, 903

*Pneumocystis jirovecci* pneumonia(PJP)/PCP

 transplant infections related to, 966--967

Pneumonia(s)

 community-acquired. *See* Community-acquired pneumonia (CAP)

 in HSCT recipients, 960--961

 late post-transplant, 961--962

* Pneumocystis jirovecci*

 transplant infections related to, 966--967

 viral, **1045--1068**. *See also specific types and* Viral pneumonia(s)

Polymyxin(s)

 for MDR GNB infections, 902--903

 for respiratory infections, 906--907

Posttransplant lymphoproliferative disorder (PTLD)

 EBV--associated

 transplant infections related to, 964--965

Prosthetic valve endocarditis (PVE), 933--935

 corynebacteria and, 934

 culture-negative, 935

 described, 933

 enterococcal, 934

 fungi and, 934

 GNB and, 934

 HACEK, 934

 staphylococcal, 933

 streptococcal, 933

*Pseudomonas aeruginosa*

 resistant

 management of, 913--914

PTLD. *See* Posttransplant lymphoproliferative disorder (PTLD)

PVE. *See* Prosthetic valve endocarditis (PVE)

Q {#sec16}
=

Quinidine

 in severe malaria management, 872

Quinine

 in severe malaria management, 872

Quinupristin-dalfopristin

 in VRE management, 843

 resistance to, 846

R {#sec17}
=

Rehabilitation

 in NSTIs management, 803

Respiratory distress

 in severe malaria, 875--876

Respiratory failure

 influenza A 2009 H1N1 and

 epidemiology of, 1072--1073

 risk factors for, 1072--1073

Respiratory infections

 aerosolized aminoglycosides for, 906--907

 polymyxins for, 906--907

Respiratory syncytial virus (RSV), 1079

 in adults, 1050--1052

 clinical manifestations of, 1051

 diagnosis of, 1051

 epidemiology of, 1050--1051

 outcomes of, 1051

 prevention of, 1051--1052

 treatment of, 1051--1052

 virology of, 1050

Respiratory virus(es)

 transplant infections related to, 965

Rifampin

 for MDR GNB infections, 902

RSV. *See* Respiratory syncytial virus (RSV)

S {#sec18}
=

SARS. *See* Severe acute respiratory syndrome (SARS)

SBP. *See* Spontaneous bacterial peritonitis (SBP)

Sepsis

* Candida*

 significance to ICU physicians, **853--864**

 catheter-related, **989--1015**. *See also* Catheter-related sepsis

 causes of, 990--992

 infusion-related, **989--1015**. *See also* Infusion-related sepsis

 introduction, 989--990

 severe

 in infective endocarditis patients in ICU

 management of, 929

Septic shock

 in infective endocarditis patients in ICU

 management of, 929

Severe acute respiratory syndrome (SARS), 1078--1079

Shock

 septic

 in infective endocarditis patients in ICU

 management of, 929

Skin and soft tissue infections (SSTIs)

 in cirrhotic patients, 815

 in diabetic patients, 809

Skin disinfection

 in catheter- and infusion-related sepsis prevention, 1004

Small intestine

 ischemia of, 1021--1032. *See also specific types, e.g.,* Acute intestinal ischemia

Solid-organ transplantation

 adenoviral infections related to, 1055--1056

Spontaneous bacterial peritonitis (SBP)

 in cirrhotic patients, 815

SSIs. *See* Surgical site infections (SSIs)

SSTIs. *See* Skin and soft tissue infections (SSTIs)

Staphylococcus(i)

 coagulase-negative

 infective endocarditis related to, 932

 infective endocarditis related to, 931

*Staphylococcus aureus*

 methicillin-resistant

 infective endocarditis related to, 932

*Stenotrophomonas maltophilia*

 resistant

 management of, 914

*Streptococcus gallolyticus*

 infective endocarditis related to, 930--931

Strongyloides hyperinfection syndrome

 transplant infections related to, 967

Sulbactam

 for MDR GNB infections, 902

Surgical site infections (SSIs), **887--894**

 defined, 887--888

 diagnosis of, 891

 epidemiology of, 888

 implanted foreign bodies and, 892

 management of, 891--892

 antimicrobial, 891--892

 initial, 891

 source control in, 892

 pathogens in, 890

 prevention of, 890--891

 risk factors for, 888--890

T {#sec19}
=

TEE. *See* Transesophageal echocardiography (TEE)

Teicoplanin

 in VRE management, 843, 845

Telavancin

 in VRE management, 845

Tigecycline

 for MDR GNB infections, 901

 in VRE management, 843

 resistance to, 847

Transesophageal echocardiography (TEE)

 in infective endocarditis diagnosis and management, 926--927

Transplant infections, **953--973**

 in abdominal organ transplant recipients, 960

 assessment of

 in early posttransplant period, 958--959

 general principles of, 955--959

 in cardiothoracic recipients, 959--960

 in HSCT recipients, 960--961

 introduction, 953--955

 late, 961--963

 CNS infection, 962--963

 enterocolitis/colitis, 963

 pneumonia, 961--962

 pathogens causing, 963--967

* Aspergillus* spp., 965--966

 CMV, 963--964

 EBV--associated PTLD, 964

 molds, 966

 PJP/PCP, 966--967

 respiratory viruses, 965

 Strongyloides hyperinfection syndrome, 967

Transplant recipients

 life-threatening infections in, **953--973**. *See also* Transplant infections

Transplantation

 solid-organ

 adenoviral infections related to, 1055--1056

Transthoracic echocardiography (TTE)

 in infective endocarditis diagnosis and management, 926--927

TTE. *See* Transthoracic echocardiography (TTE)

Tunnel infection, 991--992

Typhlitis/neutropenic enterocolitis

 in HSCT recipients, 961

U {#sec20}
=

Ulcer(s)

 perforated duodenal, 1031--1032

 surgical management of, 1037

Urinary tract infections (UTIs)

 in diabetic patients, 808

UTIs. *See* Urinary tract infections (UTIs)

V {#sec21}
=

Vancomycin

 in VRE management

 resistance to, 846

Vancomycin-resistant enterococci (VRE), **841--852**

 bacteremia due to, 842

 clinical syndromes, 842

 endocarditis due to, 842

 epidemiology of, 847

 introduction, 841

 management of, 848--849

 antimicrobial

 newer agents, 843--845

 resistance to, 845--847

 infection control in, 848

 meningitis due to, 842

 surveillance of, 848

 transmission of, 847--848

Vascular catheters

 septic risk specific to, 1001--1002

Viral pneumonia(s), **1045--1068**. *See also specific types*

 adenoviral infections, 1052--1059, 1077--1079

 adenovirus, 1077--1079

 epidemiology of, 1069--1070

 hantavirus pulmonary syndrome, 1059--1060

 hMPV, 1079--1080

 human coronavirus infections, 1046--1050

 influenza and, **1069--1086**

 RSV, 1079

 in adults, 1050--1052

 SARS, 1078--1079

Viridans streptococci

 infective endocarditis related to, 930--931

VRE. *See* Vancomycin-resistant enterococci (VRE)
